Sep 21, 2025, 07:47
WFH: Hemophilia Innovations from Factor Therapy to Gene Therapy
World Federation of Hemophilia (WFH) shared on X:
”Hemophilia has led rare disease innovation—from factor therapy to Gene Therapy—thanks to decades of advocacy and investment. But continued progress depends on sustained support. The future of treatment access is in our hands.
Read more in Blood Advances:”
Find similar posts on Hemostasis Today.
-
Feb 25, 2026, 09:14Nominations are Open for 2027 Committee and Leadership Positions – ASH
-
Feb 25, 2026, 09:08Bastu Odoka: Closing the Gap on Anti-D Prophylaxis in Maternal Care
-
Feb 25, 2026, 08:53Eiman Alzaabi: Sharing Rare Observations and Challenging Assumptions in Transfusion Medicine
-
Feb 25, 2026, 08:40Matthew Flick։ A Great Gordon Research Conference on Plasminogen Activation and Extracellular Proteolysis
-
Feb 24, 2026, 16:18Salmaan Dalvi: Mapping Rare Diseases Across East and Central Africa
-
Feb 24, 2026, 16:16Wolfgang Miesbach: Game‑Changing Data on Intensive FVIII Replacement in Haemophilia A with Hypertrophic Synovium
-
Feb 24, 2026, 16:01Is It Safe to Briefly Stop Anticoagulation After VTE? – RPTH Journal
-
Feb 24, 2026, 15:58Anastasia Conti: Honored to Receive the Roche Foundation Grant for Independent Research in Onco-Hematology
-
Feb 24, 2026, 15:55Courtney Lawrence: Targeted Donor Screening Reduces Transfusion-Transmitted Babesia Cases